Active substance Canakinumab
Domain Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen Indication extension
Main indication Lung cancer
Extended indication Gevorderd niet-kleincellig longcarcinoom, als toevoeging aan pembrolizumab en chemotherapie


Manufacturer Novartis
Mechanism of action Interleukin inhibitor
Route of administration Subcutaneous
Therapeutical formulation Injection liquid
Budgetting framework Intermural (MSZ)


Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date June 2021
Expected Registration June 2022
Orphan drug No
Registration phase Clinical trials
Additional comments Voor niet-oncologische indicaties is canakinumab reeds op de markt onder de merknaam Ilaris.

Therapeutic value

Current treatment options Pembrolizumab, nivolumab, atezolizumab, durvalumab.
Therapeutic value No judgement
Duration of treatment Not found
Frequency of administration 1 times every 3 weeks
References J Thorac Dis. 2018 Sep;10(Suppl 26):S3084-S3087. doi: 10.21037/jtd.2018.07.50 NCT03631199
Additional comments Op dit moment zijn er nog geen resultaten bekend. De gerandomiseerde fase 3 studie wordt gecompleteerd in medio 2022.

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

References FK
Additional comments Prijs per injectieflacon €11.990.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Behcet's syndrome; Pneumonia
References adisinsight
Additional comments Lopende fase 3 studies.

Other information

There is currently no futher information available.